<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TROSPIUM CHLORIDE- trospium chlorideÂ tabletÂ </strong><br>Golden State Medical Supply, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use trospium chloride safely and effectively. See full prescribing information for trospium chloride tablets.       Â        <br>      Â Â <br>Trospium chloride tablets, for oral use                <br>Initial U.S. Approval: 2004Â        </div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, Central Nervous System Effects (<a href="#i4i_section_id_53b6a1e9-d72f-42f9-941d-bb44d912adba">5.5</a>) Â 07/2012 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> (OAB) with symptoms of urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, urgency, and <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>. (<a href="#i4i_indications_id_27b603f4-c912-4c9e-b5d6-35ff704b1c81">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>The recommended dose of trospium chloride is one 20 mg tablets twice daily. Trospium chloride tablets should be dosed with water on an empty stomach, at least one hour before a meal. (<a href="#i4i_dosage_admin_id_1cc5f38a-ad1a-49f9-9c9d-429737517ef6">2</a>)</li>
<li>For patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30mL/min),the recommended dose is 20 mg once daily at bed time. (<a href="#i4i_dosage_admin_id_1cc5f38a-ad1a-49f9-9c9d-429737517ef6">2</a>)</li>
<li>In geriatric patients greater than or equal to 75 years of age, dose may be titrated down to 20 mg once daily based upon tolerability. (<a href="#i4i_dosage_admin_id_1cc5f38a-ad1a-49f9-9c9d-429737517ef6">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>20 mg tablets. (<a href="#i4i_dosage_form_strength_id_4cb2a43e-bfc5-4c0f-8d61-78bcd69a8180">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>Trospium chloride tablets are contraindicated in</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Trospium chloride tablets should be administered with caution to patients with clinically significant bladder outflow obstruction or gastrointestinal obstructive disorders due to risk of urinary or gastric retention. (<a href="#i4i_section_id_89f1fcc8-2fd4-4151-bf3b-164f9f626b43">5.1</a>,<a href="#i4i_section_id_8d864112-9794-4e5e-ac2b-194f6597e070">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, lips, tongue and/or larynx has been reported with trospium chloride. (<a href="#i4i_section_id_8e1567e0-10e5-4cfb-9e30-3e7c0ea81748">5.2</a>)</li>
<li>In patients with controlled narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> trospium chloride tablets should be used only with careful monitoring. (<a href="#i4i_section_id_4f623836-cb6f-4162-8676-3c672dd012b3">5.4</a>)</li>
<li>Central Nervous System Effects: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> has been reported with trospium chloride tablets. Advise patients not to drive or operate heavy machinery until they know how trospium chloride tablets affect them. (<a href="#i4i_section_id_53b6a1e9-d72f-42f9-941d-bb44d912adba">5.5</a>)</li>
<li>Trospium is substantially excreted by the kidney. The effects of moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on systemic exposure are not known but systemic exposure is likely increased. Therefore, the risk of anticholinergic adverse reactions is expected to be greater in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_section_id_117e715b-400e-4993-b02f-fa22e5ad4f76">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (greater than or equal to 1%) with trospium chloride tablets are <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (20.1%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (9.6%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (4.2%). (<a href="#i4i_section_id_ecc1fb13-c065-410d-a3f9-5957901eb1ef">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp., Drug Safety at 1-800-667-4708 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Concomitant use with digoxin did not affect the pharmacokinetics of either drug. (<a href="#i4i_section_id_222c59ce-40b6-42f7-b0e6-afd2994ffea6">7.1</a>)</li>
<li>Some drugs which are actively secreted by the kidney may interact with trospium chloride tablets by competing for renal tubular secretion. (<a href="#i4i_section_id_cb4e85d2-4582-4ff3-8350-8eda5ffafe05">7.2</a>)</li>
<li>Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. (<a href="#i4i_section_id_b04d46e0-4272-46fe-9071-d4ba02ab24d4">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>The safety and effectiveness of trospium chloride in pediatric patients have not been established. (<a href="#i4i_pediatric_use_id_5537c9b0-02b5-48cb-9912-6d749000841d">8.4</a>)</li></ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1 Risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span>     </a></h2>
<h2><a href="#section-6.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>     </a></h2>
<h2><a href="#section-6.3" class="toc">5.3 Decreased Gastrointestinal Motility     </a></h2>
<h2><a href="#section-6.4" class="toc">5.4Â Controlled Narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>     </a></h2>
<h2><a href="#section-6.5" class="toc">5.5Â Â Central Nervous System Effects     </a></h2>
<h2><a href="#section-6.6" class="toc">5.6 Anticholinergic Adverse Reactions in Patients with Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>      </a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1Â Clinical Trials Experience     </a></h2>
<h2><a href="#section-7.2" class="toc">6.2Â Â Post-marketing Experience</a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-8.1" class="toc">7.1 Digoxin           </a></h2>
<h2><a href="#section-8.2" class="toc">7.2Â Drugs Eliminated by Active Tubular Secretion           </a></h2>
<h2><a href="#section-8.3" class="toc">7.3 Antimuscarinic Agents     </a></h2>
<h2><a href="#section-8.4" class="toc">7.4 Metformin     </a></h2>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-9.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-9.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-9.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-9.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>     </a></h2>
<h2><a href="#section-9.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-11" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-12" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-13" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-13.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-13.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-14" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-14.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-15" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-17" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-17.1" class="toc">Storage and Handling</a></h2>
<h1><a href="#section-18" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_antibiotic_statement_id_8de2a35f-16a9-40c5-832a-5b184eb4ff24"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_27b603f4-c912-4c9e-b5d6-35ff704b1c81"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> (OAB) with symptoms of urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, urgency, and <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_1cc5f38a-ad1a-49f9-9c9d-429737517ef6"></a><a name="section-3"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is 20 mg twice daily. Trospium chloride tablets should be dosed at least one hour before meals or given on an empty stomach.Â </p>
<p>Dosage modification is recommended in the following patient populations:</p>
<ul>
<li>For patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/min), the recommended dose is 20 mg once daily at bedtime [see <a href="#i4i_section_id_53b6a1e9-d72f-42f9-941d-bb44d912adba">Warnings and Precautions (5.5)</a>, <a href="#i4i_section_id_c74a5854-07c8-4fc6-bc30-620ff26c4d67">Use in Specific Populations (8.6)</a>, and <a href="#i4i_pharmacokinetics_id_7d76c363-f886-4d79-a928-a95d30722d27">Clinical Pharmacology (12.3)</a>].</li>
<li>In geriatric patients greater than or equal to 75 years of age, dose may be titrated down to 20 mg once daily based upon tolerability [see Use in <a href="#i4i_geriatric_use_id_cac1a3c0-2e67-4f82-81b4-5d585baf912d">Specific Populations (8.5)</a>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_4cb2a43e-bfc5-4c0f-8d61-78bcd69a8180"></a><a name="section-4"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Trospium chloride tablets are supplied as 20 mg (brownish-yellow, round, biconvex, film-coated tablets, engraved â€œAPOâ€? on one side and â€œTRâ€? over â€œ20â€? on the other side).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_7c0ca03d-e977-46f6-8a08-0ed45603f779"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Trospium chloride tablets are contraindicated in patients with:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></li>
<li>gastric retention</li>
<li>uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</li>
<li>known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or its ingredients. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> have been reported.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_26564942-3053-48d4-8c44-6abb3c65ab76"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_89f1fcc8-2fd4-4151-bf3b-164f9f626b43"></a><a name="section-6.1"></a><p></p>
<h2>5.1 Risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span>     </h2>
<p class="First">Trospium chloride tablets should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> [see <a href="#i4i_contraindications_id_7c0ca03d-e977-46f6-8a08-0ed45603f779">Contraindications (4)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e1567e0-10e5-4cfb-9e30-3e7c0ea81748"></a><a name="section-6.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>     </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, lips, tongue, and/or larynx has been reported with trospium chloride, the active ingredient in trospium chloride tablets. In one case, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> occurred after the first dose of trospium chloride. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with upper airway <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, trospium chloride tablets should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.     </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d864112-9794-4e5e-ac2b-194f6597e070"></a><a name="section-6.3"></a><p></p>
<h2>5.3 Decreased Gastrointestinal Motility     </h2>
<p class="First">Trospium chloride tablets should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention [see <a href="#i4i_contraindications_id_7c0ca03d-e977-46f6-8a08-0ed45603f779">Contraindications (4)</a>]. Trospium chloride tablets, like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, intestinal atony and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4f623836-cb6f-4162-8676-3c672dd012b3"></a><a name="section-6.4"></a><p></p>
<h2>5.4Â Controlled Narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>     </h2>
<p class="First">In patients being treated for narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, trospium chloride tablets should only be used if the potential benefits outweigh the risks and in that circumstance only with careful monitoring [see <a href="#i4i_contraindications_id_7c0ca03d-e977-46f6-8a08-0ed45603f779">Contraindications (4)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_53b6a1e9-d72f-42f9-941d-bb44d912adba"></a><a name="section-6.5"></a><p></p>
<h2>5.5Â Â Central Nervous System Effects     </h2>
<p class="First">Trospium chloride tablets are associated with anticholinergic central nervous system (CNS) effects [see <a href="#i4i_section_id_8be2a454-5481-49b6-803f-367f51237ab7">Adverse Reactions (6.2)</a>]. A variety of CNS anticholinergic effects have been reported, including <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy machinery until they know how trospium chloride tablets affect them. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_117e715b-400e-4993-b02f-fa22e5ad4f76"></a><a name="section-6.6"></a><p></p>
<h2>5.6 Anticholinergic Adverse Reactions in Patients with Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>      </h2>
<p class="First">Trospium is substantially excreted by the kidney. The effects of moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on systemic exposure are not known but systemic exposure is likely increased. Therefore, anticholinergic adverse reactions (including <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>) are expected to be greater in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <a href="#i4i_dosage_admin_id_1cc5f38a-ad1a-49f9-9c9d-429737517ef6">Dosage and Administration (2)</a>, and <a href="#i4i_section_id_c74a5854-07c8-4fc6-bc30-620ff26c4d67">Use in Specific Populations (8.6)</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d1c9d7d5-9044-4b3c-b4dc-7bb9bf07925c"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ecc1fb13-c065-410d-a3f9-5957901eb1ef"></a><a name="section-7.1"></a><p></p>
<h2>6.1Â Clinical Trials Experience     </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.Â </p>
<p>The safety of trospium chloride tablets was evaluated in controlled clinical trials in a total of 2975 patients, who were treated with trospium chloride tablets (N=1673), placebo (N=1056) or active control medications (N=246). Of this total, 1181 patients participated in two, 12-week, U.S., efficacy and safety studies and a 9-month open-label extension. Of this total, 591 patients received trospium chloride tablets 20 mg twice daily. In all controlled trials combined, 232 and 208 patients received treatment with trospium chloride tablets for at least 24 and 52 weeks, respectively.Â </p>
<p>In all placebo-controlled trials combined, the incidence of serious adverse events was 2.9% among patients receiving trospium chloride tablets 20 mg twice daily and 1.5% among patients receiving placebo. Table 1 lists adverse reactions from the combined 12-week U.S. safety and efficacy trials were reported by at least 1% of patients, and were reported more frequently in the trospium chloride group than in the placebo group.</p>
<p>The two most common adverse reactions reported by patients receiving trospium chloride tablets 20 mg twice daily were <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. The single most frequently reported adverse reaction for trospium chloride tablets, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, occurred in 20.1% of trospium chloride tablets treated patients and 5.8% of patients receiving placebo. In the two U.S. studies, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> led to discontinuation in 1.9% of patients treated with trospium chloride tablets 20 mg twice daily. For the patients who reported <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, most had their first occurrence of the event within the first month of treatment.</p>
<a name="id_9259f4e2-003d-4048-a044-aec1a11f59c2"></a><table width="0.000">
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule"><td class="Botrule Lrule" align="left" colspan="3" valign="top">Table 1. Incidence (%) of adverse reactions with trospium chloride, reported in greater than or equal to 1% of all patients treated with trospium chloride and more frequent with trospium chloride (20 mg twice daily) than placebo in Studies 1 and 2 combined</td></tr>
<tr>
<td align="left" valign="top">
<span class="Bold">Adverse EventÂ </span>Â Â Â Â  </td>
<td align="left" valign="top"><span class="Bold">Placebo (N=590)</span></td>
<td align="left" valign="top"><span class="Bold">Trospium chloride 20 mg twice daily (N=591)</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="center" valign="middle">34 (5.8)</td>
<td align="center" valign="middle">119 (20.1)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center" valign="middle">27 (4.6)</td>
<td align="center" valign="middle">57 (9.6)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td align="center" valign="middle">7 (1.2)</td>
<td align="center" valign="middle">9 (1.5)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation aggravated</span></td>
<td align="center" valign="middle">5 (0.8)</td>
<td align="center" valign="middle">8 (1.4)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="middle">2 (0.3)</td>
<td align="center" valign="middle">7 (1.2)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="center" valign="middle">5 (0.8)</td>
<td align="center" valign="middle">7 (1.2)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="middle">12 (2.0)</td>
<td align="center" valign="middle">25 (4.2)</td>
</tr>
<tr>
<td align="left" valign="top">General disorders</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center" valign="middle">8 (1.4)</td>
<td align="center" valign="middle">11 (1.9)</td>
</tr>
<tr>
<td align="left" valign="top">Renal and urinary disorders</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span></td>
<td align="center" valign="middle">2 (0.3)</td>
<td align="center" valign="middle">7 (1.2)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry eyes</span> NOS</td>
<td align="center" valign="middle">2 (0.3)</td>
<td align="center" valign="middle">7 (1.2)</td>
</tr>
<tr class="Botrule Last"><td align="left" colspan="3" valign="top">Abbreviations: NOS=not otherwise specified</td></tr>
</tbody>
</table>
<p>Other adverse reactions from the U.S., placebo-controlled trials, occurring in greater than or equal to 0.5% and less than 1.0% of trospium chloride tablets treated patients, and more common with trospium chloride tablets than placebo are: <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4010026" conceptname="Pharyngeal dryness">dry throat</span>, and <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>.</p>
<p>During controlled clinical studies, one adverse reaction of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> was reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8be2a454-5481-49b6-803f-367f51237ab7"></a><a name="section-7.2"></a><p></p>
<h2>6.2Â Â Post-marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of trospium chloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Â </p>
<p>Gastrointestinal â€“ <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>; Cardiovascular â€“ <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, â€œhypertensive crisisâ€?; Immunological â€“ <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>; Nervous System â€“ <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">vision abnormal</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>; Musculoskeletal â€“ <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>; General â€“ <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.Â </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_a5070a95-4063-4eba-b186-17e2d52d724a"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_222c59ce-40b6-42f7-b0e6-afd2994ffea6"></a><a name="section-8.1"></a><p></p>
<h2>7.1 Digoxin           </h2>
<p class="First">Concomitant use of trospium chloride tablets and digoxin did not affect the pharmacokinetics of either drug [see <a href="#i4i_pharmacokinetics_id_7d76c363-f886-4d79-a928-a95d30722d27">Clinical Pharmacology (12.3)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb4e85d2-4582-4ff3-8350-8eda5ffafe05"></a><a name="section-8.2"></a><p></p>
<h2>7.2Â Drugs Eliminated by Active Tubular Secretion           </h2>
<p class="First">Although demonstrated in a drug-drug interaction study not to affect the pharmacokinetics of digoxin, trospium chloride tablets have the potential for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> with other drugs that are eliminated by active tubular secretion (e.g., procainamide, pancuronium, morphine, vancomycin, and tenofovir). Coadministration of trospium chloride tablets with these drugs may increase the serum concentration of trospium chloride tablets and/or the coadministered drug due to competition for this elimination pathway. Careful patient monitoring is recommended in patients receiving such drugs [see <a href="#i4i_pharmacokinetics_id_7d76c363-f886-4d79-a928-a95d30722d27">Clinical Pharmacology (12.3)</a>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ef80161-d326-4853-91fc-4b315197f67e"></a><a name="section-8.3"></a><p></p>
<h2>7.3 Antimuscarinic Agents     </h2>
<p class="First">The concomitant use of trospium chloride tablets with other antimuscarinic agents that produce <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. Trospium chloride tablets may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b04d46e0-4272-46fe-9071-d4ba02ab24d4"></a><a name="section-8.4"></a><p></p>
<h2>7.4 Metformin     </h2>
<p class="First">Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release tablets reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC<span class="Sub">0-24</span> and by 34% for mean C<span class="Sub">max</span> [see <a href="#i4i_pharmacokinetics_id_7d76c363-f886-4d79-a928-a95d30722d27">Clinical Pharmacology (12.3)</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_8caba25d-fc58-44b2-a4b4-aed6d547c106"></a><a name="section-9"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b47932ac-c383-4813-aae1-60af223eccc7"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_c93c4c76-b9ad-4a1d-aeda-05b82171c0e7"></a><a name="section-9.1.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Teratogenic Effects</span></span></h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_C_id_24d74bf2-a25c-467a-899a-08942a09f85e"></a><a name="section-9.1.2"></a><p></p>
<h3><span class="Bold">Pregnancy Category C:</span></h3>
<p class="First">There are no adequate and well-controlled studies of trospium chloride tablets in pregnant women. Trospium chloride tablets should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. Women who become pregnant during trospium chloride treatment are encouraged to contact their physician.</p>
<p><span class="Bold">Risk Summary</span></p>
<p>Based on animal data, trospium chloride tablets are predicted to have a low probability of increased risk of adverse developmental outcomes, above background risk. Adverse developmental findings were not observed to correlate with dose in rats or in rabbits. No increased risk above background was observed in rats and rabbits treated at an exposure approximately equivalent to the maximal recommended human dose (MRHD) of 40 mg.</p>
<p><span class="Bold">Animal Data</span></p>
<p>In a rat embryo/fetal development study, pregnant rats received doses of trospium chloride up to 200 mg/kg/day, from implantation to closure of the fetal hard palate, with maternal systemic exposures corresponding to approximately nine times the exposure of women treated at the MRHD of 40 mg, based on AUC. No malformations or fetal toxicity were observed.Â </p>
<p>The offspring of female rats exposed orally, pre- and post-natally, to trospium chloride up to 200 mg/kg/day showed no increased developmental toxicity over background in surviving pups. However, maternal toxicity (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, irregular breathing, increased <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>) was observed at 200 mg/kg/day. A no-effect level for maternal and pup toxicity (survival to Day 4) was 20 mg/kg/day, an exposure approximately equivalent to the maximal recommended human dose (MRHD) of 40 mg.Â </p>
<p>In a rabbit embryo/fetal development study, pregnant rabbits received doses of trospium chloride up to 200 mg/kg/day, from implantation to closure of the fetal hard palate. At 200 mg/kg/day, maternal systemic exposures corresponded to approximately 16 times the exposure of women treated at the MRHD of 40 mg, based on AUC. However, one fetus in each of the three treated dose groups (0.3 to 16 times exposures at the MRHD) demonstrated multiple malformations, including <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernia</span> and skeletal malformations. A maternal no-effect level was set at 20 mg/kg/day, at an exposure approximately equivalent to the maximal recommended human dose (MRHD) of 40 mg, due to clinical signs (reduced feces, hunched posture, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>) observed in a pharmacokinetic study at 200 mg/kg/day.Â        Â       </p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_488f76a5-4ac4-4847-b12c-d1bb16b2eac7"></a><a name="section-9.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of trospium chloride tablets on labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d713bede-331f-474c-8640-783f54d11941"></a><a name="section-9.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Trospium chloride (2 mg/kg orally and 50 mcg/kg intravenously) was excreted, to a limited extent (less than 1%), into the milk of lactating rats (primarily as parent compound). It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, trospium chloride tablets should be used during lactation only if the potential benefit justifies the potential risk to the newborn.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_5537c9b0-02b5-48cb-9912-6d749000841d"></a><a name="section-9.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of trospium chloride tablets in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_cac1a3c0-2e67-4f82-81b4-5d585baf912d"></a><a name="section-9.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 591 patients with <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> who received treatment with trospium chloride in the two U.S., placebo-controlled, efficacy and safety studies, 249 patients (42%) were 65 years of age and older. Eighty-eight trospium chloride tablets treated patients (15%) were greater than or equal to 75 years of age.</p>
<p>In these 2 studies, the incidence of commonly reported anticholinergic adverse reactions in patients treated with trospium chloride tablets (including <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>) was higher in patients 75 years of age and older as compared to younger patients. This effect may be related to an enhanced sensitivity to anticholinergic agents in this patient population [see <a href="#i4i_pharmacokinetics_id_7d76c363-f886-4d79-a928-a95d30722d27">Clinical Pharmacology (12.3)</a>]. Therefore, based upon tolerability, the dose frequency of trospium chloride tablets may be reduced to 20 mg once daily in patients 75 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c74a5854-07c8-4fc6-bc30-620ff26c4d67"></a><a name="section-9.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>     </h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/minute) significantly altered the disposition of trospium chloride tablets. A 4.2-fold and 1.8-fold increase in mean AUC(0-âˆž) and C<span class="Sub">max</span>, respectively, and the appearance of an additional elimination phase with a long half-life (~33 hr) were detected in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with nearly age-matched subjects with creatinine clearance equal to or higher than 80 mL/min. The different pharmacokinetic behavior of trospium chloride tablets in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> necessitates adjustment of dosage frequency [<span class="Italics">see  <a href="#i4i_dosage_admin_id_1cc5f38a-ad1a-49f9-9c9d-429737517ef6">Dosage and Administration (2)</a></span>]. The pharmacokinetics of trospium have not been studied in patients with creatinine clearance ranging from 30 to 80 mL/min.</p>
<p>Trospium is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ec4d79f-1361-4ae4-8144-7c8a029a7f76"></a><a name="section-9.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">There is no information regarding the effect of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on exposure to trospium chloride tablets. In a study of patients with mild and with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, given 40 mg of immediate-release trospium chloride, mean Cmax increased 12% and 63%, respectively, and mean AUC(0-âˆž) decreased 5% and 15%, respectively, compared to healthy subjects. The clinical significance of these findings is unknown. Caution should be used when administering trospium chloride to patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_b00c68fd-e274-483e-8c8f-2790c8cce375"></a><a name="section-10"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="i4i_controlled_substance_id_a863278b-198d-4129-8a56-065fa68a0966"></a><a name="section-10.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="i4i_abuse_id_70d2aec3-7589-423e-ab88-d0eba963e180"></a><a name="section-10.2"></a><p></p>
<h2>9.2 Abuse</h2>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="i4i_dependence_id_d1f1df2e-3336-4b8e-a56d-aa876bc13e5e"></a><a name="section-10.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_fc0776b8-3fc0-4300-9fcf-91673b62215b"></a><a name="section-11"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage with antimuscarinic agents, including trospium chloride tablets, can result in severe antimuscarinic effects. Supportive treatment should be provided according to symptoms. In the event of overdosage, electrocardiographic monitoring is recommended.</p>
<p>A 7-month-old baby experienced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> after administration of a single dose of trospium 10 mg given by a sibling. The babyâ€™s weight was reported as 5 kg. Following admission into the hospital and about 1 hour after ingestion of the trospium, medicinal charcoal was administered for detoxification. While hospitalized, the baby experienced <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> up to 230 beats per minute. Therapeutic intervention was not deemed necessary. The baby was discharged as completely recovered the following day.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_98238f8c-5bbd-4032-bb36-6577bbbcbc72"></a><a name="section-12"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Trospium chloride tablets are a quaternary ammonium compound with the chemical name of (1Î±,3Î²,5Î±)-3-[(Hydroxydiphenylacetyl)oxy]spiro[8-azoniabicyclo[3.2.1]octane-8,1â€™-pyrrolidinium] chloride. The molecular formula of trospium chloride is C<span class="Sub">25</span>H<span class="Sub">30</span>ClNO<span class="Sub">3</span> and its molecular weight is 427.96. The structural formula of trospium chloride is represented below:</p>
<div class="Figure"><img alt="Chemical Structure-Trospium chloride" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4&amp;name=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4-01.jpg"></div>
<p>Trospium chloride is a white to off-white powder. Very soluble in water.Â </p>
<p>Each trospium chloride tablet contains 20 mg of trospium chloride and is to be given orally. Each tablet also contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hydroxypropyl methylcellulose, hydroxypropylcellulose, polyethylene glycol, titanium dioxide and yellow iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_1bd789d4-a6e0-4602-b1be-574af9bcc2ff"></a><a name="section-13"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_aba37228-1586-4f0e-9147-52670d9b2125"></a><a name="section-13.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Trospium chloride tablets are a muscarinic antagonist.Â </p>
<p>Trospium chloride antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs including the bladder. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.Â </p>
<p>Receptor assays showed that trospium chloride has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses.     </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_22016ae3-37b3-48a0-873d-5997dd728f92"></a><a name="section-13.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Placebo-controlled studies employing urodynamic variables were conducted in patients with conditions characterized by involuntary detrusor contractions. The results demonstrate that trospium chloride tablets increases maximum cystometric bladder capacity and volume at first detrusor contraction.</p>
<p><span class="Bold"><span class="Italics">Electrophysiology</span></span></p>
<p>The effect of 20 mg twice daily and up to 100 mg twice daily trospium chloride tablets on QT interval was evaluated in a single-blind, randomized, placebo and active (moxifloxacin 400 mg once daily) controlled 5 day parallel trial in 170 male and female healthy volunteer subjects aged 18 to 45 years. The QT interval was measured over a 24-hour period at steady state. The 100 mg twice daily dose of trospium chloride was chosen because this achieves the C<span class="Sub">max</span>Â expected in severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Trospium chloride tablets were not associated with an increase in individual corrected (QTcI) or Fridericia corrected (QTcF) QT interval at any time during steady state measurement, while moxifloxacin was associated with a 6.4 msec increase in QTcF.Â </p>
<p>In this study, asymptomatic, non-specific T wave inversions were observed more often in subjects receiving trospium chloride tablets than in subjects receiving moxifloxacin or placebo following five days of treatment. This finding was not observed during routine safety monitoring in 2 other placebo-controlled clinical trials in 591 trospium chloride treated <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> patients [see <a href="#i4i_clinical_studies_id_ca2e0d7a-6d7c-4a34-9f78-e6f8dae6db77">Clinical Studies (14)</a>]. The clinical significance of T wave inversion in this study is unknown. Trospium chloride tablets are associated with an increase in heart rate that correlates with increasing plasma concentrations. In the study described above, trospium chloride demonstrated a mean increase in heart rate compared to placebo of 9.1 bpm for the 20 mg dose and of 18 bpm for the 100 mg dose. In the two U.S. placebo-controlled trials in patients with <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span>, the mean increase in heart rate compared to placebo in Study 1 was observed to be 3 bpm and in Study 2 was 4 bpm.     </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_7d76c363-f886-4d79-a928-a95d30722d27"></a><a name="section-13.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption</span></span></p>
<p>After oral administration, less than 10% of the dose is absorbed. Mean absolute bioavailability of a 20 mg dose is 9.6% (range: 4 to 16.1%). Peak plasma concentrations (C<span class="Sub">max</span>) occur between 5 to 6 hours post-dose. Mean C<span class="Sub">max</span>Â increases greater than dose-proportionally; a 3-fold and 4-fold increase in C<span class="Sub">max</span>Â was observed for dose increases from 20 mg to 40 mg and from 20 mg to 60 mg, respectively. AUC exhibits dose linearity for single doses up to 60 mg. Trospium chloride tablets exhibit diurnal variability in exposure with a decrease in C<span class="Sub">max</span>Â and AUC of up to 59% and 33%, respectively, for evening relative to morning doses.</p>
<p><span class="Bold"><span class="Italics">Effect of Food</span></span></p>
<p>Administration with a high (50%) fat-content meal resulted in reduced absorption, with AUC and C<span class="Sub">max</span> values 70 to 80% lower than those obtained when trospium chloride was administered while fasting. Therefore, it is recommended that trospium chloride tablets should be taken at least one hour prior to meals or on an empty stomach [see <a href="#i4i_dosage_admin_id_1cc5f38a-ad1a-49f9-9c9d-429737517ef6">Dosage and Administration (2)</a>].</p>
<p>A summary of mean (Â± standard deviation) pharmacokinetic parameters for a single 20 mg dose of trospium chloride tablets is provided in Table 2.</p>
<a name="id_3bdb7ae2-8138-443f-aec7-88ecda5cbdd8"></a><table width="0.000">
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule"><td class="Botrule Lrule" align="left" colspan="4" rowspan="1" valign="top">Table 2 : Mean (Â±SD) Pharmacokinetic Parameter Estimates for a Single 20 mg Trospium Chloride Tablets Dose in Healthy Volunteers</td></tr>
<tr>
<td align="left" valign="top">Cmax (ng/mL)</td>
<td align="left" valign="top">AUC 0-âˆž(ng/mL Â· hr)</td>
<td align="left" valign="top">Tmax (hr)</td>
<td align="left" valign="top">t1/2 (hr)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">3.5 Â± 4.0</td>
<td align="left" valign="top">36.4 Â± 21.8</td>
<td align="left" valign="top">5.3 Â± 1.2</td>
<td align="left" valign="top">18.3 Â± 3.2</td>
</tr>
</tbody>
</table>
<p>The mean plasma concentration-time (+ SD) profile for trospium chloride tablets is shown in Figure 1.</p>
<p><span class="Bold">Figure 1 - Mean (+ SD) Concentration-Time Profile for a Single 20 mg Oral Dose of Trospium Chloride Tablets in Healthy Volunteers</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4&amp;name=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4-02.jpg"></div>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Protein binding ranged from 50 to 85% when concentration levels of trospium chloride (0.5 to 50 ng/mL) were incubated with human serum in vitro. Â </p>
<p>The <span class="Sup">3</span>H-trospium chloride ratio of plasma to whole blood was 1.6:1. This ratio indicates that the majority of <span class="Sup">3</span>H-trospium chloride is distributed in plasma.Â </p>
<p>The apparent volume of distribution for a 20 mg oral dose is 395 (Â± 140) liters.Â </p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>The metabolic pathway of trospium in humans has not been fully defined. Of the 10% of the dose absorbed, metabolites account for approximately 40% of the excreted dose following oral administration. The major metabolic pathway is hypothesized as ester hydrolysis with subsequent conjugation of benzylic acid to form azoniaspironortropanol with glucuronic acid. Cytochrome P450 (CYP) is not expected to contribute significantly to the elimination of trospium. Data taken from in vitro human liver microsomes investigating the inhibitory effect of trospium on seven CYP isoenzyme substrates (CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4) suggest a lack of inhibition at clinically relevant concentrations.</p>
<p><span class="Bold"><span class="Italics">Excretion</span></span></p>
<p>The plasma half-life for trospium chloride tablets following oral administration is approximately 20 hours. After oral administration of an immediate-release formulation of <span class="Sup">14</span>C-trospium chloride, the majority of the dose (85.2%) was recovered in feces and a smaller amount (5.8% of the dose) was recovered in urine; 60% of the radioactivity excreted in urine was unchanged trospium.Â </p>
<p>The mean renal clearance for trospium (29.07 L/hour) is 4-fold higher than average glomerular filtration rate, indicating that active tubular secretion is a major route of elimination for trospium. There may be competition for elimination with other compounds that are also renally eliminated [<span class="Italics">see <a href="#i4i_section_id_cb4e85d2-4582-4ff3-8350-8eda5ffafe05">Drug Interactions (7.2)</a></span>].     </p>
<p><span class="Bold"><span class="Italics">Drug Interactions</span></span></p>
<p><span class="Underline">Digoxin</span>: Concomitant use of 20 mg (trospium chloride immediate release tablets) twice daily at steady state and a single dose of 0.5 mg digoxin in a crossover study with 40 male and female subjects did not affect the pharmacokinetics of either drug.</p>
<p><span class="Underline">Metformin</span>: A drug interaction study was conducted in which trospium chloride 60 mg extended release tabletsonce daily was co-administered with GlucophageÂ® (metformin hydrochloride) 500 mg twice daily under steady-state conditions in 44 healthy subjects. Co-administration of 500 mg metformin immediate release tablets twice daily reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC<span class="Sub">0-24</span> and by 34% for mean C<span class="Sub">max</span>. The effect of decrease in trospium exposure on the efficacy of trospium chloride tablets is unknown. The steady-state pharmacokinetics of metformin were comparable when administered with or without 60 mg trospium chloride extended release tablets once daily under fasted condition. The effect of metformin at higher doses on trospium PK is unknown.    </p>
<p><span class="Bold"><span class="Italics">Specific Populations</span></span></p>
<p><span class="Underline">Age:</span>Age did not appear to significantly affect the pharmacokinetics of trospium chloride, however, increased anticholinergic side effects unrelated to drug exposure were observed in patients greater than or equal to 75 years of age [see <a href="#i4i_geriatric_use_id_cac1a3c0-2e67-4f82-81b4-5d585baf912d">8.5 Geriatric Use</a>].Â </p>
<p><span class="Underline">Pediatric:</span> The pharmacokinetics of trospium chloride tablets were not evaluated in pediatric patients. Â </p>
<p><span class="Underline">Race</span>: Pharmacokinetic differences due to race have not been studied.Â </p>
<p><span class="Underline">Gender</span>: Studies comparing the pharmacokinetics in different genders had conflicting results. When a single 40 mg trospium chloride tablets dose was administered to 16 elderly subjects, exposure was 45% lower in elderly females compared to elderly males. When 20 mg trospium chloride tablets were dosed twice daily for 4 days to 6 elderly males and 6 elderly females (60 to 75 years), AUC and C<span class="Sub">max</span> were 26% and 68% higher, respectively, in females without hormone replacement therapy than in males.Â </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>: In a clinical pharmacokinetic study where a single dose of 40 mg immediate release trospium chloride tablets was administered to 12 healthy males and 12 males with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/minute) significantly altered the disposition of trospium chloride tablets. A 4.2-fold and 1.8-fold increase in mean AUC(0-âˆž) and C<span class="Sub">max</span>, respectively, and the appearance of an additional elimination phase with a long half-life (~33 hours vs. 18 hours) were detected in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with nearly age-matched subjects with creatinine clearance equal to or higher than 80 mL/min. The different pharmacokinetic behavior of trospium chloride tablets in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> necessitates adjustment of dosage frequency [see <a href="#i4i_dosage_admin_id_1cc5f38a-ad1a-49f9-9c9d-429737517ef6">Dosage and Administration (2)</a>]. The pharmacokinetics of trospium have not been studied in patients with creatinine clearance ranging from 30 to 80 mL/min.Â </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: In a clinical pharmacokinetic study in patients with mild (Child-Pugh score 5 to 6) and with moderate (Child-Pugh score 7 to 8) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, given a single dose of 40 mg immediate-release trospium chloride tablets, mean C<span class="Sub">max</span> increased 12% and 63%, respectively, and mean AUC(0-âˆž) decreased 5% and 15%, respectively, compared to healthy subjects. There is no information regarding the effect of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on exposure to trospium chloride tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_4504646e-e305-441e-8b65-89531648de87"></a><a name="section-14"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_f8d6c9ae-a6e3-4f67-ad84-627860040a13"></a><a name="section-14.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold"><span class="Italics">Carcinogenesis</span></span></p>
<p>Carcinogenicity studies with trospium chloride tablets were conducted in mice and rats for 78 weeks and 104 weeks, respectively, at maximally tolerated doses. No evidence of a carcinogenic effect was found in either mice or rats administered up to 200 mg/kg/day, approximately 9 times the expected clinical exposure levels at the maximum recommended human dose (MRHD) of 40 mg. Â </p>
<p><span class="Bold"><span class="Italics">Mutagenesis</span></span></p>
<p>Trospium chloride was not mutagenic nor genotoxic in tests in vitro in bacteria (Ames test) and mammalian cells (L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and CHO cells) or in vivo in the rat micronucleus test.Â </p>
<p><span class="Bold"><span class="Italics">Impairment of Fertility</span></span></p>
<p>No evidence of impaired fertility was observed in rats administered doses up to 200 mg/kg/day (about 16 times the expected clinical exposure at the MRHD, based on AUC).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_52f68e83-519e-461d-a25a-db72a6f8e182"></a><a name="section-14.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_ca2e0d7a-6d7c-4a34-9f78-e6f8dae6db77"></a><a name="section-15"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Trospium chloride tablets were evaluated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> who had symptoms of <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, urgency, and <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span> in two U.S. 12-week, placebo-controlled studies and one 9-month open label extension.Â </p>
<p><span class="Bold">Study 1</span> was a randomized, double-blind, placebo-controlled, parallel-group study in 523 patients. A total of 262 patients received trospium chloride 20 mg twice daily and 261 patients received placebo. The majority of patients were Caucasian (85%) and female (74%) with a mean age of 61 years (range: 21 to 90 years). Entry criteria required that patients have urge or mixed <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> (with a predominance of urge), <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span> episodes of at least 7 per week, and greater than 70 micturitions per week. The patientâ€™s medical history and urinary diary during the treatment-free baseline confirmed the diagnosis. Reductions in <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span> episodes and urinary void volume for placebo and trospium chloride tablets treatment groups are summarized in Table 3 and Figures 2 and 3.</p>
<a name="id_5f843404-f8d3-4731-a1c1-d199dc5db06d"></a><table width="431">
<col width="46.9%">
<col width="15.5%">
<col width="23.0%">
<col width="14.6%">
<tbody class="Headless">
<tr class="First Toprule"><td class="Botrule Lrule" align="left" colspan="4" valign="top">Table 3. Mean (SE) change from baseline to end of treatment (Week 12 or last observation carried forward) for <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span> episodes, and void volume in Study 1.</td></tr>
<tr>
<td align="left" valign="top">Efficacy endpoint</td>
<td align="left" valign="top">Placebo N=256</td>
<td align="left" valign="top">Trospium chloride N=253</td>
<td align="left" valign="top">P-value</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>/24hoursa,*</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â Mean baseline</td>
<td align="left" valign="top">12.9</td>
<td align="left" valign="top">12.7</td>
<td align="left" valign="top">&lt;0.001</td>
</tr>
<tr>
<td align="left" valign="top">Mean change from baseline</td>
<td align="left" valign="top">-1.3 (0.2)</td>
<td align="left" valign="top">-2.4 (0.2)</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">Urge incontinence</span> episodes/weekb,*</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Mean baseline</td>
<td align="left" valign="top">30.1</td>
<td align="left" valign="top">27.3</td>
<td align="left" valign="top">0.012</td>
</tr>
<tr>
<td align="left" valign="top">Mean change from baseline</td>
<td align="left" valign="top">-13.9 (1.2)</td>
<td align="left" valign="top">-15.4 (1.1)</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Urinary void volume/toilet void (mL) a,c</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Mean baseline</td>
<td align="left" valign="top">156.6</td>
<td align="left" valign="top">155.1</td>
<td align="left" valign="top">&lt;0.001</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Mean change from baseline</td>
<td align="left" valign="top">7.7 (3.1)</td>
<td align="left" valign="top">32.1 (3.1)</td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>Treatment differences assessed by analysis of variance for ITT:LOCF data set</p>
<p><span class="Sup">b </span>Treatment differences assessed by ranked analysis of variance for ITT: LOCF data set.Â     </p>
<p><span class="Sup">c</span>Placebo N=253, Trospium chloride N=248</p>
<p>*Denotes co-primary endpoint</p>
<p>ITT= intent to treat, LOCF=last observation carried forward</p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4&amp;name=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4-03.jpg"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4&amp;name=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4-04.jpg"><span class="Bold">Study 2 </span>was nearly identical in design to Study 1. A total of 329 patients received trospium chloride 20 mg twice daily and 329 patients received placebo. The majority of patients were Caucasian (88%) and female (82%) with a mean age of 61 years (range: 19 to 94 years). Entry criteria were identical to Study 1. Reductions in <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span> episodes, and urinary void volume for placebo and trospium chloride treatment groups are summarized in Table 4 and Figures 4 and 5.</p>
<a name="id_67bb1f8e-1fa6-43e8-a263-1a0c242d8b26"></a><table border="1" width="431">
<col width="45.9%">
<col width="14.6%">
<col width="23.9%">
<col width="15.5%">
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="4" valign="top"><span class="Bold">Table 4. Mean (SE) change from baseline to end of treatment (Week 12 or last observation carried forward) for <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span> episodes, and void volume in Study 2.Â </span></td></tr>
<tr>
<td align="left" valign="top"><span class="Bold">Efficacy endpoint</span></td>
<td align="center" valign="top"><span class="Bold">Placebo N=325</span></td>
<td align="center" valign="top"><span class="Bold">Trospium chloride N=323</span></td>
<td align="center" valign="top"><span class="Bold">P-value</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>/24hours<span class="Sup">a</span>,* </span></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top"></td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td align="left" valign="middle">Mean baseline</td>
<td align="center" valign="top">13.2</td>
<td align="center" valign="top">12.9</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="middle">Mean change from baseline</td>
<td align="center" valign="top">-1.8 (0.2)</td>
<td align="center" valign="top">-2.7 (0.2)</td>
<td align="center" valign="top">&lt;0.001</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">Urge incontinence</span> episodes/week<span class="Sup">b</span></span></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â Â </td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="middle">Mean baseline</td>
<td align="center" valign="top">27.3</td>
<td align="center" valign="top">26.9</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="middle">Mean change from baseline</td>
<td align="center" valign="top">-12.1 (1.0)</td>
<td align="center" valign="top">-16.1 (1.0)</td>
<td align="center" valign="top">&lt;0.001</td>
</tr>
<tr>
<td align="left" valign="middle"><span class="Bold">Urinary void volume/toilet void (mL) <span class="Sup">a,c</span></span></td>
<td align="center" valign="top">Â Â </td>
<td align="center" valign="top"></td>
<td align="center" valign="top">Â Â Â </td>
</tr>
<tr>
<td align="left" valign="middle">Mean baseline</td>
<td align="center" valign="top">154.6</td>
<td align="center" valign="top">154.8</td>
<td align="center" valign="top"></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="middle">Mean change from baseline</td>
<td align="center" valign="top">9.4 (2.8)</td>
<td align="center" valign="top">35.6 (2.8)</td>
<td align="center" valign="top">&lt;0.001</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>Treatment differences assessed by analysis of variance for ITT:LOCF data set</p>
<p><span class="Sup">b </span>Treatment differences assessed by ranked analysis of variance for ITT: LOCF data set.</p>
<p><span class="Sup">c</span>Placebo N=320, Trospium chloride N=319</p>
<p>*Denotes co-primary endpoint</p>
<p>ITT= intent to treat, LOCF=last observation carried forward</p>
<div class="Figure"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4&amp;name=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4-05.jpg"></div>
<div class="Figure"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4&amp;name=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_22ecf96a-abf9-4bb9-826c-8479d7aa5120"></a><a name="section-16"></a><p></p>
<h1>15 REFERENCES</h1>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_e8c3418a-9ef9-4e67-8f15-8b5c6c4be416"></a><a name="section-17"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Trospium chloride tablets 20 mg (brownish-yellow, round, biconvex, film-coated tablets, engraved â€œAPOâ€? on one side and â€œTRâ€? over â€œ20â€? on the other side) are supplied as follows:</p>
<p>Bottles of 60Â Â Â  Â Â Â NDC 60429-103-60</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_56528f65-ed90-4cd1-92f7-f69c2289e73d"></a><a name="section-17.1"></a><p></p>
<h2>Storage and Handling</h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_4610ea5c-f724-480c-bac9-ea75366eb321"></a><a name="section-18"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">â€œSee FDA-approved Patient Labeling (Patient Information)â€?Â </p>
<p><span class="Bold">17.1Â <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></p>
<p>Patients should be informed that trospium chloride, the active ingredient in trospium chloride tablets, may produce <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> which could result in life-threatening airway obstruction. Patients should be advised to promptly discontinue trospium chloride tablets and seek immediate medical attention if they experience <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the tongue, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the laryngopharynx, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>.Â </p>
<p><span class="Bold">17.2Â When Not to Use</span></p>
<p>Â Prior to treatment, patients should fully understand the risks and benefits of trospium chloride tablets. In particular, patients should be informed not to take trospium chloride tablets if they: </p>
<ul>
<li>have <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>; </li>
<li>gastric retention; </li>
<li>uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>; </li>
<li>are allergic to any component of trospium chloride tablets. Â Â </li>
</ul>
<p><span class="Bold">17.3Â Â Â Â  Administration</span></p>
<p>    Â Patients should be instructed regarding the recommended dosing and administration of trospium chloride tablets: </p>
<ul>
<li>Take one trospium chloride tablet twice daily with water. </li>
<li>Take trospium chloride tablets on an empty stomach or at least 1 hour before a meal. Â </li>
</ul>
<p><span class="Bold">17.4Â Adverse Reactions</span></p>
<p>Â Patients should be informed that the most common side effects with trospium chloride tablets are <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and that other less common side effects include trouble emptying the bladder, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, and <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span>. Because anticholinergics, such as trospium chloride, may produce <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drugâ€™s effects have been determined. Patients should be informed that alcohol may enhance the <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> caused by anticholinergic agents.</p>
<p>Â </p>
<p>Manufactured by:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Manufactured for:               Marketed/Packaged by: </p>
<p>Apotex Inc.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Apotex Corp.                       <span class="Bold">GSMS, Inc. </span></p>
<p>Toronto, OntarioÂ Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â Weston, Florida,                  Camarillo, CA </p>
<p>Canada, M9L 1T9Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  33326 USAÂ                         93012</p>
<p>Revision: 5</p>
<p>Revised: November 2012</p>
<p><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">Trospium Chloride Tablets</span></p>
<p>Read the Patient Information that comes with trospium chloride tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.Â </p>
<p><span class="Bold">What are trospium chloride tablets?</span></p>
<p>Trospium chloride tablets are a prescription medicine used to treat adults with <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> who have the following symptoms:</p>
<ul>
<li>a strong need to urinate right away;</li>
<li>leaking or wetting <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span> due to a strong need to urinate right away;</li>
<li>a need to urinate often.</li>
</ul>
<p><span class="Bold">Who should not take trospium chloride tablets?</span></p>
<p>Do not take trospium chloride tablets if you:</p>
<ul>
<li>have trouble emptying your bladder;</li>
<li>have delayed or slow emptying of your stomach;</li>
<li>have an eye problem called â€œuncontrolled narrow-angle glaucomaâ€?;</li>
<li>are allergic to trospium chloride tablets or any of its ingredients. See the end of this leaflet for a complete list of ingredients.</li>
</ul>
<p>Trospium chloride tablets have not been studied in children under the age of 18 years.</p>
<p><span class="Bold">What should I tell my doctor before starting trospium chloride tablets?</span></p>
<p>Tell your doctor about all of your medical conditions including if you:Â     </p>
<ul>
<li>have any stomach or intestinal problems or problems with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>;</li>
<li>have trouble emptying your bladder or have a weak urine stream;</li>
<li>have an eye problem called narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>;</li>
<li>have kidney problems;</li>
<li>have liver problems;</li>
<li>are pregnant or planning to become pregnant. It is not known if trospium chloride can harm your Â unborn baby.</li>
<li>are breastfeeding. It is not known if trospium chloride passes into breast milk and if it can harmÂ  your baby.</li>
</ul>
<p>You should talk to your doctor about the best way to feed your baby if you are taking trospium chloride tablets.</p>
<p>Tell your doctor about all the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Trospium chloride tablets and certain other medicines can interact and make some side effects worse. Trospium chloride tablets can affect how other medicines are handled by the body.</p>
<p>Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist each time you get a new medicine.</p>
<p><span class="Bold">How should I take trospium chloride tablet?</span></p>
<p>Take trospium chloride tablets exactly as prescribed.</p>
<ul>
<li>Take one trospium chloride tablet twice daily with water.</li>
<li>Take trospium chloride tablets on an empty stomach or at least 1 hour before a meal.</li>
<li>If you take too much trospium chloride, call your local Poison Control Center or go to an emergency room right away.</li>
</ul>
<p><span class="Bold">What are the possible side effects of trospium chloride?</span></p>
<p>Trospium chloride may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> that may be serious. Symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, throat or tongue. If you experience these symptoms, you should stop taking trospium chloride tablets and get emergency medical help right away.Â </p>
<p>The most common side effects with trospium chloride tablets are:Â     </p>
<ul>
<li>drymouth;</li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>;</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</li>
</ul>
<p>Â Trospium chloride tablets may cause other less common side effects, including:</p>
<ul>
<li>trouble emptying the bladder;</li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Do not drive or operate heavy machinery until you know how trospium chloride tablets affect you. Alcohol can worsen the <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> caused by drugs such as trospium chloride tablets.</li>
<li><span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span>. Due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> can occur when drugs such as trospium chloride tablets are used in a hot environment.</li>
</ul>
<p>Tell your doctor if you have any side effects that bother you or that do not go away.Â These are not all possible side effects of trospium chloride tablets. For more information, ask your doctor, healthcare professional or pharmacist.</p>
<p><span class="Bold">How should I store trospium chloride tablets?</span></p>
<ul>
<li>Keep trospium chloride tablets and all other medicines out of the reach of children.</li>
<li>Store trospium chloride tablets at room temperature, 68Â° to 77Â°F (20Â° to 25Â°C).</li>
<li>Safely dispose of trospium chloride tablets that are out of date or that you no longer need.</li>
</ul>
<p><span class="Bold">General information about trospium chloride tablets</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use trospium chloride tablets for a condition for which it was not prescribed. Do not give trospium chloride tablets to other people, even if they have the same symptoms you have. It may harm them.Â </p>
<p>This leaflet summarizes the most important information about trospium chloride tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about trospium chloride tablets that is written for health professionals. </p>
<p><span class="Bold">What are the ingredients in trospium chloride tablets?</span></p>
<p>Each tablet contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hydroxypropyl methylcellulose, hydroxypropylcellulose, polyethylene glycol, titanium dioxide and yellow iron oxide.Â </p>
<p>Manufactured by:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Manufactured for:                 Marketed/Packaged by: </p>
<p>Apotex Inc.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Apotex Corp.                         <span class="Bold">GSMS, Inc. </span></p>
<p>Toronto, OntarioÂ Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â Weston, Florida,                    Camarillo, CA </p>
<p>Canada, M9L 1T9Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  33326 USAÂ                           93012</p>
<p>Revision: 0</p>
<p>Revised: November 2012 </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_40174680-4a86-4020-8ad6-e8806261c034"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">GSMS Inc.</span> NDC 60429-103-60 </p>
<p><span class="Bold">Trospium Chloride Tablets</span></p>
<p>20 mg</p>
<p><span class="Bold">Rx</span></p>
<p>60 bottle tablets</p>
<div class="Figure"><img alt="Label Graphic- 20mg 60s" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4&amp;name=0ac65eae-b3dd-4cda-aec2-ff1e954a93a4-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TROSPIUM CHLORIDEÂ 		
					</strong><br><span class="contentTableReg">trospium chloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60429-103(NDC:60505-3454)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TROSPIUM CHLORIDE</strong> (TROSPIUM) </td>
<td class="formItem">TROSPIUM CHLORIDE</td>
<td class="formItem">20Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2906 (4000 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">score with uneven pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;TR;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60429-103-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091513</td>
<td class="formItem">02/08/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Golden State Medical Supply, Inc.
							(603184490)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Golden State Medical Supply, Inc.</td>
<td class="formItem"></td>
<td class="formItem">603184490</td>
<td class="formItem">REPACK(60429-103), RELABEL(60429-103)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0ac65eae-b3dd-4cda-aec2-ff1e954a93a4</div>
<div>Set id: 0ac65eae-b3dd-4cda-aec2-ff1e954a93a4</div>
<div>Version: 1</div>
<div>Effective Time: 20130103</div>
</div>
</div>Â <div class="DistributorName">Golden State Medical Supply, Inc.</div></p>
</body></html>
